David A. Siegel Axsome Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 3,400 shares of AXSM stock, worth $308,482. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,400

Holding current value

$308,482

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$78.93 - $95.84 $268,362 - $325,856	3,400 New	3,400 $305,000
Q2 2022 Aug 15, 2022	SELL	$21.74 - $46.75 $821,771 - $1.77 Million	-37,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.7 - $41.39 $154,050 - $269,035	6,500 Added 20.77%	37,800 $1.57 Million
Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $85,960 - $121,408	-2,800 Reduced 8.21%	31,300 $1.18 Million
Q3 2021 Nov 15, 2021	SELL	$19.91 - $68.26 $286,704 - $982,944	-14,400 Reduced 29.69%	34,100 $1.12 Million
Q2 2021 Aug 16, 2021	SELL	$50.63 - $73.5 $4.11 Million - $5.97 Million	-81,200 Reduced 62.61%	48,500 $3.27 Million
Q1 2021 May 17, 2021	BUY	$55.91 - $81.44 $2.71 Million - $3.94 Million	48,400 Added 59.53%	129,700 $7.34 Million
Q4 2020 Feb 16, 2021	SELL	$66.31 - $86.52 $1.76 Million - $2.3 Million	-26,600 Reduced 24.65%	81,300 $6.62 Million
Q3 2020 Nov 16, 2020	SELL	$68.34 - $85.84 $881,586 - $1.11 Million	-12,900 Reduced 10.68%	107,900 $7.69 Million
Q2 2020 Aug 14, 2020	BUY	$49.87 - $98.69 $134,649 - $266,463	2,700 Added 2.29%	120,800 $9.94 Million
Q1 2020 May 15, 2020	BUY	$41.2 - $101.31 $3.77 Million - $9.26 Million	91,400 Added 342.32%	118,100 $6.95 Million
Q4 2019 Feb 14, 2020	BUY	$16.71 - $106.24 $446,157 - $2.84 Million	26,700 New	26,700 $2.76 Million

Others Institutions Holding AXSM

# of Institutions

325

Shares Held

37.7M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.89B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account